Development of Methyl Isoxazoleazepines As Inhibitors of BET
Overview
Authors
Affiliations
In this report we detail the evolution of our previously reported thiophene isoxazole BET inhibitor chemotype exemplified by CPI-3 to a novel bromodomain selective chemotype (the methyl isoxazoleazepine chemotype) exemplified by carboxamide 23. The methyl isoxazoleazepine chemotype provides potent inhibition of the bromodomains of the BET family, excellent in vivo PK across species, low unbound clearance, and target engagement in a MYC PK-PD model.
Muddassir M, Soni K, Sangani C, Alarifi A, Afzal M, Abduh N RSC Adv. 2022; 11(2):612-636.
PMID: 35746919 PMC: 9133982. DOI: 10.1039/d0ra07971e.
Yang S, Yoshioka M, Strovel J, Urban D, Hu X, Hall M Bioorg Med Chem Lett. 2019; 29(10):1220-1226.
PMID: 30905542 PMC: 7405260. DOI: 10.1016/j.bmcl.2019.03.014.
Targeting Brd4 for cancer therapy: inhibitors and degraders.
Duan Y, Guan Y, Qin W, Zhai X, Yu B, Liu H Medchemcomm. 2018; 9(11):1779-1802.
PMID: 30542529 PMC: 6238758. DOI: 10.1039/c8md00198g.
Dietary Compound Resveratrol Is a Pan-BET Bromodomain Inhibitor.
Dutra L, Heidenreich D, Silva G, Chin C, Knapp S, Dos Santos J Nutrients. 2017; 9(11).
PMID: 29077030 PMC: 5707644. DOI: 10.3390/nu9111172.
Drug Discovery Targeting Bromodomain-Containing Protein 4.
Liu Z, Wang P, Chen H, Wold E, Tian B, Brasier A J Med Chem. 2017; 60(11):4533-4558.
PMID: 28195723 PMC: 5464988. DOI: 10.1021/acs.jmedchem.6b01761.